Aurobindo Pharma Gets FDA Green Light for Asthma Inhaler

Aurobindo Pharma has announced it received final approval from the U.S. FDA to manufacture and market its Beclomethasone Dipropionate HFA Inhalation Aerosol. This product, available in 40 mcg and 80 mcg strengths, is a generic version of Teva's QVAR Inhalation Aerosol. This approval signifies a major step for Aurobindo as it represents the company's first metered-dose inhaler and its strategic expansion into complex respiratory therapies.

The manufacturing of this new product will take place at the subsidiary Aurolife Pharma's facility located in Raleigh, North Carolina. Aurobindo anticipates launching the inhaler in the upcoming quarters. The U.S. market for this approved product and its reference drug versions was valued at $301 million for the twelve months concluding in July 2026, according to IQVIA data. Aurobindo aims to leverage this into a "next wave of differentiated growth in the U.S. market."